Compare Harmony Gold Mining Co. (HMY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Tango Therapeutics Inc. — how do they compare? Harmony Gold Mining Co. trades at $16.47 (market cap $10.37B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Harmony Gold Mining Co. is far larger — about 2.8× Tango Therapeutics Inc.'s market cap, and Harmony Gold Mining Co. pays a 4.67% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Tango Therapeutics Inc. for 0 Days on average.
| HMY | TNGX | |
|---|---|---|
Market Cap | $10.37B | $3.75B |
Volume | 2,951,252 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $32.90 |
52-Week Low | $13.32 | $7.50 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $10.42B | $2.77B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.29, down 2.34% today, amid bearish technical signals but strong fundamentals. The stock shows robust revenue growth from $42.6B in 2022 to $73.9B in 2025, with net income surging to $14.4B. Valuation ratios remain attractive with P/E of 5.96 and EV/EBITDA of 3.64. Recent earnings showed mixed results with two beats and two misses in the last four quarters.
The outlook is cautiously optimistic given strong profitability metrics (ROE 46.23%, net margin 29.57%) and copper expansion plans, though technical weakness and analyst skepticism (70% hold rating) suggest near-term volatility. Key risks include gold price dependency and execution challenges in diversification efforts.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
